Enlivex is implementing a drastic cost reduction plan, including a 60% workforce cut and significant management salary reductions, to prioritize funding for its Phase 2b Allocetra trial. This move signals a critical pivot for the company, focusing all resources on a single, high-stakes clinical program, with topline data expected by mid-2027.
Enlivex has announced a severe cost-cutting measure, including a 60% reduction in its workforce and significant cuts to management salaries, to conserve cash. This strategic shift is designed to fully fund and prioritize the Phase 2b clinical trial of Allocetra for knee osteoarthritis, winding down all other non-clinical R&D. This is a high-stakes move for Enlivex, as the company is essentially betting its future on the success of this single trial. For traders, this presents a binary outcome: short-term volatility due to the drastic restructuring, followed by a long-term opportunity or risk depending on the trial's success, with key data expected by mid-2027.